- Home
- HP vs ARWR Comparison
HP vs ARWR Comparison
Compare HP & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HP
- ARWR
- Stock Information
- Founded
- HP 1920
- ARWR 2003
- Country
- HP United States
- ARWR United States
- Employees
- HP N/A
- ARWR N/A
- Industry
- HP Oil & Gas Production
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- HP Energy
- ARWR Health Care
- Exchange
- HP Nasdaq
- ARWR Nasdaq
- Market Cap
- HP 3.0B
- ARWR 2.7B
- IPO Year
- HP N/A
- ARWR 1993
- Fundamental
- Price
- HP $30.44
- ARWR $19.45
- Analyst Decision
- HP Hold
- ARWR Buy
- Analyst Count
- HP 9
- ARWR 12
- Target Price
- HP $38.57
- ARWR $42.70
- AVG Volume (30 Days)
- HP 1.6M
- ARWR 2.3M
- Earning Date
- HP 01-27-2025
- ARWR 02-04-2025
- Dividend Yield
- HP 0.82%
- ARWR N/A
- EPS Growth
- HP N/A
- ARWR N/A
- EPS
- HP 3.43
- ARWR N/A
- Revenue
- HP $2,756,607,000.00
- ARWR $3,551,000.00
- Revenue This Year
- HP $23.09
- ARWR $4,225.26
- Revenue Next Year
- HP $11.05
- ARWR $59.48
- P/E Ratio
- HP $8.89
- ARWR N/A
- Revenue Growth
- HP N/A
- ARWR N/A
- 52 Week Low
- HP $29.46
- ARWR $17.05
- 52 Week High
- HP $44.11
- ARWR $39.83
- Technical
- Relative Strength Index (RSI)
- HP 31.11
- ARWR 39.31
- Support Level
- HP $32.56
- ARWR $21.48
- Resistance Level
- HP $32.90
- ARWR $22.47
- Average True Range (ATR)
- HP 1.25
- ARWR 1.33
- MACD
- HP -0.47
- ARWR -0.53
- Stochastic Oscillator
- HP 8.99
- ARWR 3.46
About HP Helmerich & Payne Inc.
Helmerich & Payne maintains one of the largest fleets of land drilling rigs in the US. The company's FlexRig line is the leading choice to drill horizontal wells for production of US tight oil and gas. H&P is present in nearly every major US shale play and has a small but growing presence internationally.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.